Back to results
US 12,746,230 B2Granted
Anticancer compositions
AssigneeAragon Pharmaceuticals, Inc.
InventorsJohny Bertels, Matthieu Garin, Florentina Maria Preda, Reshema Kemps-Polanco
Life of this patent
Estimating the term…
Abstract
The present invention concerns pharmaceutical formulations of apalutamide, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer.
Claims24
A tablet comprising an intragranular phase and an extragranular phase, wherein the intragranular phase comprises:
- a solid dispersion comprising
- (apalutamide) and hydroxypropyl methylcellulose acetate succinate (HPMCAS), and
- a pharmaceutically acceptable carrier comprising a glidant and a disintegrant, wherein the solid dispersion is present at equal or greater than 80 w/w % relative to the total weight of the tablet.
A tablet comprising an intragranular phase and an extragranular phase, wherein the intragranular phase comprises:
- a solid dispersion comprising
- (apalutamide) and hydroxypropyl methylcellulose acetate succinate (HPMCAS),
- colloidal anhydrous silica, and
- croscarmellose sodium,
- and wherein the extragranular phase comprises:
- silicified microcrystalline cellulose
- colloidal anhydrous silica,
- croscarmellose sodium, and
- magnesium stearate,
- and wherein the solid dispersion is present at equal or greater than 80 w/w % relative to the total weight of the tablet.
7 more elements
Dependencies are inferred from the claim text.